Progressive myoclonus epilepsy

Progressive myoclonus epilepsy[1]
Progressive myoclonic epilepsy type 1-a,b) MRI c) FLAIR
SpecialtyNeurology

Progressive Myoclonic Epilepsies (PME) are a rare group of inherited neurodegenerative diseases characterized by myoclonus, resistance to treatment, and neurological deterioration.[2] The cause of PME depends largely on the type of PME. Most PMEs are caused by autosomal dominant or recessive and mitochondrial mutations.[2] The location of the mutation also affects the inheritance and treatment of PME. Diagnosing PME is difficult due to their genetic heterogeneity and the lack of a genetic mutation identified in some patients.[3] The prognosis depends largely on the worsening symptoms and failure to respond to treatment. There is no current cure for PME and treatment focuses on managing myoclonus and seizures through antiepileptic medication (AED).[3][2]

The age of onset depends on the specific PME but PME can affect people of all ages. In Unverricht-Lundborg disease (ULD) the age of onset is between 6–15 years, while in Adult Neuronal ceroid lipofuscinoses (Adult NCL) the age of onset can be as late as 30.[2]

Symptoms often include action or stimuli induced myoclonus, seizures, neuropathy, cognitive decline, and spike and wave or no cerebral discharges.[4] The prognosis of those diagnosed with PME is poor, the person often becomes wheelchair bound, enters a vegetative state due to myoclonus, and has shortened life expectancy.[4][3]

Signs and symptoms

The most common symptom of PME is myoclonus.[2] The myoclonus can be fragmented or multifocal and can be triggered by posture, actions, and external stimuli such as light, sound, and touch.[2] The type of myoclonus differs between the types of PME. Other symptoms of PME include generalized, tonic clonic, tonic, and atypical absence seizures.[4] In Lafora’s disease the seizures are occipital and the person experiences transient blindness as well as visual hallucinations.[4][5] The person may also have atypical absences and atonic and complex partial seizures. In Myoclonus epilepsy with ragged-red fibers (MERRF) the person experiences generalized epilepsy along with myoclonus, weakness, and dementia.[4][5]

As PME progresses neurological ability decreases and can lead to myopathy, neuropathy, cognitive decline, cerebellar ataxia, and dementia.[4][2] The different symptoms in each of the PME and between individuals makes diagnosis difficult. Therefore, diagnosis of PME is dependent on failure to respond to antiepileptic drugs and therapy but diagnosis of specific PME depends on genetic testing, EEG (electroencephalography), enzyme measurements and more.[4][2][3]

Cause

Specific disorders

Several conditions can cause progressive myoclonic epilepsy.

Unverricht-Lundborg disease

Main article: Unverricht–Lundborg disease

This disease manifests between six and sixteen years and is most prevalent in Scandinavia and the Baltic countries. Myoclonus gradually becomes worse and less susceptible to medication. Cognitive decline is slow and sometimes mild. Patients typically do not live beyond middle-age, but there are exceptions. Phenytoin, an old and commonly used anticonvulsant, is known to seriously exacerbate the condition. It has autosomal recessive inheritance, and is caused by a mutation in the cystatin B (EPM1) gene on chromosome 21q22.3, which was discovered in 1996.

It has been described as the least severe type of PME.[7]

Myoclonus epilepsy and ragged red fibres (MERRF syndrome)

Main article: MERRF syndrome

Onset of this disease may be at any time and the severity and progression are varied. Tonic-clonic seizures and dementia are less apparent than with other forms of PME. The cause is a mitochondrial DNA mutation, so most familial cases are transmitted from the mother. A skeletal muscle biopsy will show ragged red fibres, hence the name.

Lafora body disease

Main article: Lafora disease

This disease typically begins between six and nineteen years after apparently normal development and generally results in death within ten years. It is characterised by the presence of Lafora bodies (polyglucosan inclusions) in neurons and other body tissue. The generalized seizures are usually well controlled by anticonvulsants, but the myoclonus soon proves refractory to treatment. Within a couple of years, a wheelchair is required for locomotion and within five to ten years, the person is confined to bed and is often tube fed. Valproic acid and zonisamide are first choice anticonvulsants, and the ketogenic diet may be helpful. An autosomal-recessive genetic defect is responsible, which has been tracked down to two genes. The EPM2A gene on chromosome 6q24 was discovered in 1998 and encodes for the protein laforin. It is responsible for 80% of cases. The EPM2B gene on chromosome 6p22.3 was discovered in 2003 and encodes for the protein malin. There may be a third gene of unknown locus.

Neuronal ceroid lipofuscinoses

Main article: Neuronal ceroid lipofuscinosis

There are various forms of these disorders, each with their own genetic cause and geographical variation, which lead to accumulation of lipopigments (lipofuscin) in the body's tissues and are inherited in an autosomal-recessive fashion. Onset and symptoms vary with the particular form, but death usually occurs within five to fifteen years.

Type I sialidosis

Main article: Sialidosis

This is an autosomal recessive disorder in which the body is deficient in α-neuraminidase.

Myoclonic epilepsy and ataxia due to potassium (K+) channel mutation (MEAK)

MEAK is a form of progressive myoclonus epilepsy that typically begins between the ages of 3 and 15 years (the average of onset is 10 years). The first symptoms may include ataxia and myoclonus (unsteadiness and difficulty coordinating movements), along with generalized tonic-clonic (“grand mal”) seizures. Individuals with MEAK typically do not experience developmental delays. The symptoms are progressive, and individuals with MEAK often need to use a wheelchair by their late teenage years because of movement difficulties and myoclonus. Many individuals with MEAK report temporary improvement of symptoms when they have a high fever. Seizures may become less frequent in adulthood, but other neurological complications, including myoclonus, ataxia and tremor, may worsen. Myoclonic epilepsy and ataxia due to potassium (K+) channel mutation (MEAK) is caused by a specific pathogenic variant (“mutation”) in KCNC1 (c.959G>A; p.Arg320His). KCNC1-related developmental and epileptic encephalopathy is associated with other pathogenic variants in KCNC1. In most individuals with KCNC1-related disorders, the pathogenic KCNC1 variant occurred spontaneously (de novo) and was not inherited from either parent.

Diagnosis

Diagnosis of PME is based on the individual’s signs and symptoms as well as failure to respond to antiepileptic drugs and therapy.[3] Further diagnosis support includes EEG results, genetic testing, enzyme testing, and skin and muscle biopsies.[2] Gaucher’s disease can be diagnosed through enzyme testing as it is a metabolic disease.[4] Lafora’s disease can be diagnosed using skin biopsies.[4] While Action myoclonus renal failure (AMRF) syndrome can only be diagnosed using genetic test.[4] Using EEG’s as a form of diagnosis can prove difficult as patients differ in their neurophysiology. In Lafora’s disease EEGs can show slowing background activity or focal discharges as well as epileptiform discharges.[3] In ULD EEGs show generalized epileptiform discharges and in MERRF patients show background slowing.[2] Therefore, diagnosis is best made using a combination of different tools like signs and symptoms, age of onset, EEG, gene testing, enzyme measurements, and biopsy of skin and muscle.[4]

Differential diagnosis

The main component setting PME apart from other forms of epilepsy is progressive deterioration and resistance to treatment.[2] Therefore, in the early stages of PME the symptoms and EEG may appear like Generalized epilepsy, Juvenile myoclonic epilepsy, benign childhood myoclonic epilepsy, and Huntington’s disease.[3] It is crucial for ensure initial treatment is appropriate to measure how the condition progresses. Incorrect treatment can also result in wrong PME diagnosis.[2][3]

Management

The is no cure for PME. Efforts are instead placed in managing the symptoms, specifically the myoclonus and seizures as these can cause major harm to the individual.[2] However, treating the symptoms with antiepileptic drugs can be difficult because PME individuals can become resistant. Some antiepileptic drugs used in treatment are valproic acid, benzodiazepines, phehobarbital, piracetam, zonisamide, clonazepam, and levetiracetam. It is important to note that some antiepileptic drugs can worsen the symptoms, like vigabatrin, carbamazepine, phenytoin, and gabapentin.[2][3] Clonazepam is currently the only drug approved by the FDA for monotherapy treatment of myoclonic seizures.[3] Other treatments that have been used in PME patients are deep brain stimulation, vagus nerve stimulation , and diet but they have not been shown to improve seizures.[2][3]

Prognosis

The prognosis of PME is ultimately dependent on the type of PME. In Lafora body disease the neurological deterioration progresses until resulting in a vegetative state and death within 10 years of diagnosis.[4] Due to research and advances in antiepileptic medication, individuals with ULD can live up to 60 years of age.[2] In others severe myoclonus can lead to injury by falling and becoming wheelchair bound.[2]

Epidemiology

PME accounts for less than 1% of epilepsy cases at specialist centres. The incidence and prevalence of PME is unknown, but there are considerable geography and ethnic variations amongst the specific genetic disorders. One cause, Unverricht Lundborg Disease, has an incidence of at least 1:20,000 in Finland.[8]

Research

Because PME is so rare it is hard to do studies specifically double blind studies used to test different antiepileptic drugs. The wide range of symptoms including the differing EEG makes studying the effects of the AEDs difficult.[4]  In ULD, oligonucleotide therapeutic strategies have been used to replace gene effects while in Sialidosis enzyme replacement therapy has been studied in mouse models.[9] In Lafora’s disease metformin has been approved for treatment by the European commission.[9] In MERRF bacterial proteins have been identified in treatment in mitochondrial diseases but further studies are needed.[9]

History

The first instance where myoclonus and its relationship to epilepsy was in 1822 by Prichard.[10] Lundborg was the first to name progressive myoclonus epilepsy in 1903 due to his study of several Swedish families as well as research done by Heinrich Unverricht in 1891.[10] However, ULD was not recognized as a disease until a century later due to the rarity of the disease.[10] In 1911, Lafora identified Lafora bodies but believed to be part of ULD. Lafora’s genetics was not described until 1995.[10]

See also

References

  1. ↑ Berg AT, Berkovic SF, Brodie MJ, et al. (April 2010). "Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009". Epilepsia. 51 (4): 676–85. doi:10.1111/j.1528-1167.2010.02522.x. PMID 20196795.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Shahwan, Amre; Farrell, Michael; Delanty, Norman (April 2005). "Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects". The Lancet Neurology. 4 (4): 239–248. doi:10.1016/s1474-4422(05)70043-0. ISSN 1474-4422. Archived from the original on 2022-01-11. Retrieved 2022-01-04.
  3. 1 2 3 4 5 6 7 8 9 10 11 Holmes, Gregory L. (April 1, 2020). "Drug Treatment of Progressive Myoclonic Epilepsy". Paediatr Drugs. 22(2): 149–164 – via HHS Public Access.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 Malek, Stewart, Greene, Naveed, William, John (February 26, 2015). "The progressive myoclonic epilepsies". Pract Neurol. 15: 164–171 – via BMJ.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. 1 2 Delgado-Escueta, Ganesh, Yamakawa, A.V., Subramaniam, Kazuhiro (2001). "Advances in the Genetics of Progressive Myoclonus Epilepsy". American Journal of Medical Genetics. 106: 129–138 – via AJMG.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ↑ Wirrell, Elaine (2016). "Infantile, Childhood, and Adolescent Epilepsies". CONTINUUM: Lifelong Learning in Neurology. 22 (1, Epilepsy): 60–93. doi:10.1212/con.0000000000000269. PMID 26844731. Archived from the original on 2022-01-11. Retrieved 2022-01-04.
  7. ↑ Genton P (2006). "[Unverricht-Lundborg disease (PME1)]". Rev. Neurol. (Paris) (in français). 162 (8–9): 819–26. doi:10.1016/S0035-3787(06)75084-6. PMID 17028542.{{cite journal}}: CS1 maint: url-status (link)
  8. ↑ "Unverricht-Lundborg Disease". Retrieved 2008-01-26.
  9. 1 2 3 Orsini, Alessandro; Valetto, Angelo; Bertini, Veronica; Esposito, Mariagrazia; Carli, Niccolò; Minassian, Berge A.; Bonuccelli, Alice; Peroni, Diego; Michelucci, Roberto; Striano, Pasquale (October 2019). "The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy". Seizure. 71: 247–257. doi:10.1016/j.seizure.2019.08.012. ISSN 1059-1311. Archived from the original on 2022-01-11. Retrieved 2022-01-04.
  10. 1 2 3 4 Genton, Striano, Minassian, Pierre, Pasquale, Berge A. (2016). "The history of progressive myoclonus epilepsies". Epileptic Disord. 18: S3–S10 – via Pudmed.{{cite journal}}: CS1 maint: multiple names: authors list (link)
Classification
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.